320 related articles for article (PubMed ID: 32231294)
1. Cancer stemness in hepatocellular carcinoma: mechanisms and translational potential.
Tsui YM; Chan LK; Ng IO
Br J Cancer; 2020 May; 122(10):1428-1440. PubMed ID: 32231294
[TBL] [Abstract][Full Text] [Related]
2. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
[TBL] [Abstract][Full Text] [Related]
3. Road to stemness in hepatocellular carcinoma.
Flores-Téllez TN; Villa-Treviño S; Piña-Vázquez C
World J Gastroenterol; 2017 Oct; 23(37):6750-6776. PubMed ID: 29085221
[TBL] [Abstract][Full Text] [Related]
4. Lipopolysaccharide supports maintaining the stemness of CD133(+) hepatoma cells through activation of the NF-κB/HIF-1α pathway.
Lai FB; Liu WT; Jing YY; Yu GF; Han ZP; Yang X; Zeng JX; Zhang HJ; Shi RY; Li XY; Pan XR; Li R; Zhao QD; Wu MC; Zhang P; Liu JF; Wei LX
Cancer Lett; 2016 Aug; 378(2):131-41. PubMed ID: 27208741
[TBL] [Abstract][Full Text] [Related]
5. Musashi 2 contributes to the stemness and chemoresistance of liver cancer stem cells via LIN28A activation.
Fang T; Lv H; Wu F; Wang C; Li T; Lv G; Tang L; Guo L; Tang S; Cao D; Wu M; Yang W; Wang H
Cancer Lett; 2017 Jan; 384():50-59. PubMed ID: 27721018
[TBL] [Abstract][Full Text] [Related]
6. Tex10 is upregulated and promotes cancer stem cell properties and chemoresistance in hepatocellular carcinoma.
Xiang X; Deng L; Xiong R; Xiao D; Chen Z; Yang F; Liu K; Feng G
Cell Cycle; 2018; 17(11):1310-1318. PubMed ID: 30045663
[TBL] [Abstract][Full Text] [Related]
7. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway.
Li B; Cao Y; Meng G; Qian L; Xu T; Yan C; Luo O; Wang S; Wei J; Ding Y; Yu D
EBioMedicine; 2019 Jan; 39():239-254. PubMed ID: 30555042
[TBL] [Abstract][Full Text] [Related]
8. A novel model of liver cancer stem cells developed from induced pluripotent stem cells.
Afify SM; Sanchez Calle A; Hassan G; Kumon K; Nawara HM; Zahra MH; Mansour HM; Khayrani AC; Alam MJ; Du J; Seno A; Iwasaki Y; Seno M
Br J Cancer; 2020 Apr; 122(9):1378-1390. PubMed ID: 32203212
[TBL] [Abstract][Full Text] [Related]
9. Cancer Stem Cell Functions in Hepatocellular Carcinoma and Comprehensive Therapeutic Strategies.
Liu YC; Yeh CT; Lin KH
Cells; 2020 May; 9(6):. PubMed ID: 32466488
[TBL] [Abstract][Full Text] [Related]
10. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma.
Chen J; Jin R; Zhao J; Liu J; Ying H; Yan H; Zhou S; Liang Y; Huang D; Liang X; Yu H; Lin H; Cai X
Cancer Lett; 2015 Oct; 367(1):1-11. PubMed ID: 26170167
[TBL] [Abstract][Full Text] [Related]
11. CPEB1 mediates hepatocellular carcinoma cancer stemness and chemoresistance.
Xu M; Fang S; Song J; Chen M; Zhang Q; Weng Q; Fan X; Chen W; Wu X; Wu F; Tu J; Zhao Z; Ji J
Cell Death Dis; 2018 Sep; 9(10):957. PubMed ID: 30237545
[TBL] [Abstract][Full Text] [Related]
12. BORIS up-regulates OCT4 via histone methylation to promote cancer stem cell-like properties in human liver cancer cells.
Liu Q; Chen K; Liu Z; Huang Y; Zhao R; Wei L; Yu X; He J; Liu J; Qi J; Qin Y; Li B
Cancer Lett; 2017 Sep; 403():165-174. PubMed ID: 28645561
[TBL] [Abstract][Full Text] [Related]
13. Long Non-Coding RNAs as Mediators of Tumor Microenvironment and Liver Cancer Cell Communication.
Lin YH; Wu MH; Yeh CT; Lin KH
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30477236
[TBL] [Abstract][Full Text] [Related]
14. C-terminal truncated hepatitis B virus X protein regulates tumorigenicity, self-renewal and drug resistance via STAT3/Nanog signaling pathway.
Ching RHH; Sze KMF; Lau EYT; Chiu YT; Lee JMF; Ng IOL; Lee TKW
Oncotarget; 2017 Apr; 8(14):23507-23516. PubMed ID: 28186991
[TBL] [Abstract][Full Text] [Related]
15. ZnAs@SiO
Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H
Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768
[No Abstract] [Full Text] [Related]
16. Liver tumor-initiating cells as a therapeutic target for hepatocellular carcinoma.
Lee TK; Cheung VC; Ng IO
Cancer Lett; 2013 Sep; 338(1):101-9. PubMed ID: 22579789
[TBL] [Abstract][Full Text] [Related]
17. The biological implication of cancer stem cells in hepatocellular carcinoma: a possible target for future therapy.
Sukowati CH; Tiribelli C
Expert Rev Gastroenterol Hepatol; 2013 Nov; 7(8):749-57. PubMed ID: 24161136
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma.
Dai X; Guo Y; Hu Y; Bao X; Zhu X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Fang W
Theranostics; 2021; 11(7):3489-3501. PubMed ID: 33537099
[TBL] [Abstract][Full Text] [Related]
19. Prx2 links ROS homeostasis to stemness of cancer stem cells.
Son YW; Cheon MG; Kim Y; Jang HH
Free Radic Biol Med; 2019 Apr; 134():260-267. PubMed ID: 30611866
[TBL] [Abstract][Full Text] [Related]
20. Resolvin D1 prevents epithelial-mesenchymal transition and reduces the stemness features of hepatocellular carcinoma by inhibiting paracrine of cancer-associated fibroblast-derived COMP.
Sun L; Wang Y; Wang L; Yao B; Chen T; Li Q; Liu Z; Liu R; Niu Y; Song T; Liu Q; Tu K
J Exp Clin Cancer Res; 2019 Apr; 38(1):170. PubMed ID: 30999932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
